



GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

March 20, 2025

- *The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology*
- *Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality*
- *The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care*

CHICAGO--(BUSINESS WIRE)--Mar. 20, 2025-- GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts.

Approximately 71% of cancers occur in dense breasts.¹ According to studies across the U.S. and Europe, 40% of women² and 70% of Asian women³ have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis.⁴ Early detection of breast cancer is critical, yet about one-third⁵ of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. There is rapidly growing evidence supporting ABUS as a valuable tool for detecting cancer in dense breasts because it provides clearer and more detailed images and has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography.^{6,7,8,9}

"Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimize clinicians' screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts," said Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare. "Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritizing the patient experience with features to improve scan speed and enhance comfort during an exam."

Invenia ABUS Premium is designed to manage high patient volumes along the breast care pathway, while delivering extraordinary image quality and boosting clinical confidence. The new Verisound™ A tools can help clinicians work smarter and more efficiently, featuring Scan Quality Assessment for immediate qualitative evaluation during the exam for proper breast coverage and positioning, and Auto Nipple Detection for consistent nipple marker positions. The new Fast Scan tool increases scan speed by up to 40%*, while cSound™ Imageformer capabilities automatically create focus at every pixel, ensuring consistent, high-resolution image quality and reproducibility.

For fast, streamlined reading, physicians can use Invenia ABUS Viewer with AI Assistant** to quickly review and interpret patient exams either from their practice or remotely. The integration of AI tools** for enhanced review of ABUS 3D datasets harness intelligent algorithms to assist in detecting and characterizing breast lesions. These tools can help improve clinical confidence and reading efficiency, addressing staff shortages.

The ABUS Premium's non-invasive design significantly enhances the patient experience, with a patient experience study showing that 100% of women would recommend an ABUS exam to their best friend.¹⁰ This advanced ABUS technology also has the potential to reduce unnecessary biopsies by providing specific image features to distinguish and detect malignant tumors, enabling clinicians to escalate care sooner.⁹ Additionally, it reduces patient exposure to radiation or contrast injection as it doesn't use any iodinated contrast agent or ionizing radiation. The new Reverse Curve™ transducer follows the contour of a woman's breast anatomy, while selectable compression levels provide personalized comfort during the exam.

"As an early adopter of ABUS, I've experienced the entire evolution of this technology. The Invenia ABUS Premium is superior* with its special AI features, which ensure the breast volume is captured and offer automatic nipple annotation, reducing scanning time and streamlining clinical workflow," said Athina Vourtsis, MD, PhD, Chief Director and Founder of Athena Medical, Athens, Greece; Founding President of the Hellenic Breast Imaging Society; European Liaison and Member of the Medical Advisory Board of DenseBreast-Info. "The new Reverse Curve transducer makes the examination more patient friendly, and it is much more comfortable. There has been great improvement in image quality with less shadowing, and the structures behind the area of the nipple are seen more clearly, providing radiologists with greater diagnostic confidence."

Invenia ABUS Premium will be launching in key countries throughout 2025 and received Premarket Approval (PMA) from the U.S. Food and Drug Administration. Invenia ABUS Premium was featured at the 2025 European Congress of Radiology (ECR) and will also be showcased at the National Consortium of Breast Centers (NCoBC) 2025 and 2025 Society of Breast Imaging (SBI) Symposium.

Learn more about GE HealthCare's Invenia ABUS Premium here: [Invenia ABUS Breast Imaging Ultrasound | GE HealthCare \(United States\)](#)

*Compared to Invenia™ ABUS 2.0.

**AI Assistant available third-party tools include QVCAD™, Koios DS™ Breast, BU-CAD™ and MONCAD ABS. Not available in all regions.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and

integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a \$19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among [2025 Fortune World's Most Admired Companies™](#).

Follow us on [LinkedIn](#), [X](#), [Facebook](#), [Instagram](#), and [Insights](#) for the latest news, or visit our website <https://www.gehealthcare.com> for more information.

¹ Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18.

² Pisano et al. NEJM 2005; 353: 1773.

³ Ref. Ellison-Loschman, et al, PLOS ONE July 2013.

⁴ Boyd NF et al. NEJM 2007; 356: 227

⁵ Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.

⁶ FDA PMA P110006 summary of safety and effectiveness

⁷ Brem RF, Tabár L, et.al. Radiology. 2015 Mar; 274(3): 663-73.

⁸ Stempel et.al., Journal of Breast Imaging 2024, Vol XX, No. XX, 1-10.

⁹ Wenhui Ren et. al, Elsevier Acad Radiol 2023; 30:S114–S126.

¹⁰ Shah et.al. Journal of Diagnostic Medical Sonography DOI: 10.1177/8756479313476920 2013.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250320743877/en/): <https://www.businesswire.com/news/home/20250320743877/en/>

GE HealthCare Media Contact

Eric Tatro

GE HealthCare

+1 312 459 6140

Eric.Tatro@gehealthcare.com

Source: GE HealthCare